169 related articles for article (PubMed ID: 22798348)
1. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys.
Véniant MM; Komorowski R; Chen P; Stanislaus S; Winters K; Hager T; Zhou L; Wada R; Hecht R; Xu J
Endocrinology; 2012 Sep; 153(9):4192-203. PubMed ID: 22798348
[TBL] [Abstract][Full Text] [Related]
2. A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys.
Stanislaus S; Hecht R; Yie J; Hager T; Hall M; Spahr C; Wang W; Weiszmann J; Li Y; Deng L; Winters D; Smith S; Zhou L; Li Y; Véniant MM; Xu J
Endocrinology; 2017 May; 158(5):1314-1327. PubMed ID: 28324011
[TBL] [Abstract][Full Text] [Related]
3. FGF21 decreases body weight without reducing food intake or bone mineral density in high-fat fed obese rhesus macaque monkeys.
Andersen B; Straarup EM; Heppner KM; Takahashi DL; Raffaele V; Dissen GA; Lewandowski K; Bödvarsdottir TB; Raun K; Grove KL; Kievit P
Int J Obes (Lond); 2018 Jun; 42(6):1151-1160. PubMed ID: 29892039
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice.
Weng Y; Chabot JR; Bernardo B; Yan Q; Zhu Y; Brenner MB; Vage C; Logan A; Calle R; Talukdar S
PLoS One; 2015; 10(3):e0119104. PubMed ID: 25790234
[TBL] [Abstract][Full Text] [Related]
5. Increased fibroblast growth factor 21 expression in high-fat diet-sensitive non-human primates (Macaca mulatta).
Nygaard EB; Møller CL; Kievit P; Grove KL; Andersen B
Int J Obes (Lond); 2014 Feb; 38(2):183-91. PubMed ID: 23736354
[TBL] [Abstract][Full Text] [Related]
6. Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes.
Hecht R; Li YS; Sun J; Belouski E; Hall M; Hager T; Yie J; Wang W; Winters D; Smith S; Spahr C; Tam LT; Shen Z; Stanislaus S; Chinookoswong N; Lau Y; Sickmier A; Michaels ML; Boone T; Véniant MM; Xu J
PLoS One; 2012; 7(11):e49345. PubMed ID: 23209571
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic effect of fibroblast growth factor 21 on hypertension induced by insulin resistance].
Zhu SL; Ren GP; Zhang ZY; Wang WF; Ye XL; Han MM; Zhao JZ; Xu TY; Liu MY; Li DS
Yao Xue Xue Bao; 2013 Sep; 48(9):1409-14. PubMed ID: 24358774
[TBL] [Abstract][Full Text] [Related]
8. Preparation, characterization, and pharmacological study of a novel long-acting FGF21 with a potential therapeutic effect in obesity.
Kim D; Lee J; Bae I; Kim M; Huh Y; Choi J; Bae S; Choi IY; Kim HH; Kim DK
Biologicals; 2021 Jan; 69():49-58. PubMed ID: 33277119
[TBL] [Abstract][Full Text] [Related]
9. Serum fibroblast growth factor 21 in human obesity: regulation by insulin infusion and relationship with glucose and lipid oxidation.
Strączkowski M; Karczewska-Kupczewska M; Adamska A; Otziomek E; Kowalska I; Nikołajuk A
Int J Obes (Lond); 2013 Oct; 37(10):1386-90. PubMed ID: 23419601
[TBL] [Abstract][Full Text] [Related]
10. FGF21 decreases food intake and body weight in obese Göttingen minipigs.
Christoffersen B; Straarup EM; Lykkegaard K; Fels JJ; Sass-Ørum K; Zhang X; Raun K; Andersen B
Diabetes Obes Metab; 2019 Mar; 21(3):592-600. PubMed ID: 30328263
[TBL] [Abstract][Full Text] [Related]
11. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.
Hale C; Chen MM; Stanislaus S; Chinookoswong N; Hager T; Wang M; Véniant MM; Xu J
Endocrinology; 2012 Jan; 153(1):69-80. PubMed ID: 22067317
[TBL] [Abstract][Full Text] [Related]
12. Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice.
Camacho RC; Zafian PT; Achanfuo-Yeboah J; Manibusan A; Berger JP
Eur J Pharmacol; 2013 Sep; 715(1-3):41-5. PubMed ID: 23831019
[TBL] [Abstract][Full Text] [Related]
13. Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates.
Kim AM; Somayaji VR; Dong JQ; Rolph TP; Weng Y; Chabot JR; Gropp KE; Talukdar S; Calle RA
Diabetes Obes Metab; 2017 Dec; 19(12):1762-1772. PubMed ID: 28573777
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody.
Huang J; Ishino T; Chen G; Rolzin P; Osothprarop TF; Retting K; Li L; Jin P; Matin MJ; Huyghe B; Talukdar S; Bradshaw CW; Palanki M; Violand BN; Woodnutt G; Lappe RW; Ogilvie K; Levin N
J Pharmacol Exp Ther; 2013 Aug; 346(2):270-80. PubMed ID: 23720456
[TBL] [Abstract][Full Text] [Related]
15. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21.
Müller TD; Sullivan LM; Habegger K; Yi CX; Kabra D; Grant E; Ottaway N; Krishna R; Holland J; Hembree J; Perez-Tilve D; Pfluger PT; DeGuzman MJ; Siladi ME; Kraynov VS; Axelrod DW; DiMarchi R; Pinkstaff JK; Tschöp MH
J Pept Sci; 2012 Jun; 18(6):383-93. PubMed ID: 22565812
[TBL] [Abstract][Full Text] [Related]
16. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.
Xu J; Stanislaus S; Chinookoswong N; Lau YY; Hager T; Patel J; Ge H; Weiszmann J; Lu SC; Graham M; Busby J; Hecht R; Li YS; Li Y; Lindberg R; Véniant MM
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1105-14. PubMed ID: 19706786
[TBL] [Abstract][Full Text] [Related]
17. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice.
Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Patel K; Bahekar R; Shah G; Jain M
Can J Physiol Pharmacol; 2013 Dec; 91(12):1009-15. PubMed ID: 24289070
[TBL] [Abstract][Full Text] [Related]
18. Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.
Weng Y; Ishino T; Sievers A; Talukdar S; Chabot JR; Tam A; Duan W; Kerns K; Sousa E; He T; Logan A; Lee D; Li D; Zhou Y; Bernardo B; Joyce A; Kavosi M; O'Hara DM; Clark T; Guo J; Giragossian C; Stahl M; Calle RA; Kriz R; Somers W; Lin L
Sci Rep; 2018 Mar; 8(1):4241. PubMed ID: 29523796
[TBL] [Abstract][Full Text] [Related]
19. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.
Gaich G; Chien JY; Fu H; Glass LC; Deeg MA; Holland WL; Kharitonenkov A; Bumol T; Schilske HK; Moller DE
Cell Metab; 2013 Sep; 18(3):333-40. PubMed ID: 24011069
[TBL] [Abstract][Full Text] [Related]
20. A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects.
Talukdar S; Zhou Y; Li D; Rossulek M; Dong J; Somayaji V; Weng Y; Clark R; Lanba A; Owen BM; Brenner MB; Trimmer JK; Gropp KE; Chabot JR; Erion DM; Rolph TP; Goodwin B; Calle RA
Cell Metab; 2016 Mar; 23(3):427-40. PubMed ID: 26959184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
